Two C-methyl derivatives of [11C]WAY-100635 -: Effects of an amido α-methyl group on metabolism and brain 5-HT1A receptor radioligand behavior in monkey

被引:6
|
作者
McCarron, JA
Marchais-Oberwinkler, S
Pike, VW
Tarkiainen, J
Halldin, C
Sóvagó, J
Gulyas, BZ
Wikström, HV
Farde, L
机构
[1] Hammersmith Hosp, Imperial Coll Sch Med, MRC Cyclotron Unit, London W12 0NN, England
[2] Univ Groningen, Univ Ctr Pharm, Dept Med Chem, NL-9713 AV Groningen, Netherlands
[3] Karolinska Inst, Karolinska Hosp, Dept Clin Neurosci, Psychiat Sect, S-17176 Stockholm, Sweden
关键词
5-HT1A receptors; PET; radioligand; WAY-100635; alpha-methyl; metabolism; carbon-11;
D O I
10.1007/s11307-005-4127-5
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: [carbonyl-C-11]N-(2-(1-(4-(2-methoxyphenyl)-piperazinyl)ethyl)-N-pyridinyl)cyclohexanecarboxamide ([carbonyl-C-11]WAY-100635) is an effective radioligand for imaging brain 5-HT1A receptors with positron emission tomography (PET). However, this radioligand has some drawbacks for deriving relative regional receptor densities, including rapid metabolism, which acts against accurate definition of an arterial input function for compartmental modeling, and very low nonspecific binding in brain, which detracts from the accuracy of modeling by a simplified reference tissue (cerebellum) approach. Here, in a search for a radioligand that overcomes these limitations, we investigated the effects of introducing a single methyl group at either of the carbon atoms alpha to the amide bond in [C-11]WAY-100635. Procedures: Ligands with a methyl group on the alpha carbon of the cyclohexyl group (SWAY) or the alpha carbon of the C2H4 linker ((R,S)-JWAY) were synthesized and tested for binding affinity and intrinsic activity at 5-HT1A receptors. SWAY was labeled with carbon-11 (t(1/2) = 20.4 minutes; beta(+) = 99.8%) in its O-methyl group and (R,S)-JWAY in its carbonyl group. Each radioligand was evaluated by PET experiments in cynomolgus monkey. Results: SWAY and (R,S)-JWAY were found to be high-affinity antagonists at 5-HT1A receptors. After injection of [C-11]SWAY into monkey, radioactivity uptake in brain reached a maximum of 3% at 4.5 minutes and decreased to 0.7% at 72 minutes. However, over the time span of the experiment, radioactivity concentrations in 5-HT1A receptor-rich brain regions were only fractionally higher than in cerebellum. Radioactivity represented by parent radioligand in plasma was 39% at 45 minutes. After injection of [C-11](R,S)-JWAY alone, radioactivity uptake in brain reached a maximum of 4.8% at 2.5 minutes and decreased to 1.2% at 90 minutes. At this time, radioactivity concentration in 5-HT1A receptor-rich brain regions was markedly greater than in cerebellum. In another PET experiment, the monkey was predosed with WAY-100635 before [C-11](R,S)-JWAY injection. At 90 minutes after injection, the ratio of radioactivity in 5-HT1A receptor-rich regions to that in cerebellum was reduced to near unity. Radioactivity represented by parent radioligand in plasma was 12% at 45 minutes. Conclusions: [C-11](R,S)-JWAY, but not [C-11]SWAY, gives a sizeable 5-HT1A receptor-selective PET signal in monkey. The presence of a C-methyl group adjacent to the amide bond in SWAY or (R,S)-JWAY fails to counter metabolism.
引用
收藏
页码:209 / 219
页数:11
相关论文
共 50 条
  • [1] Two C-Methyl Derivatives of [11C]WAY-100635 – Effects of an Amido α-Methyl Group on Metabolism and Brain 5-HT1A Receptor Radioligand Behavior in Monkey*
    Julie A. McCarron
    Sandrine Marchais-Oberwinkler
    Victor W. Pike
    Jari Tarkiainen
    Christer Halldin
    Judit Sóvagó
    Balàzs Gulyas
    Hakan V. Wikström
    Lars Farde
    [J]. Molecular Imaging and Biology, 2005, 7 : 209 - 219
  • [2] Evaluation of two C-methyl derivatives of 11C-WAY-100635 as potential radioligands for 5-HT1A receptors.
    Pike, V
    Tarkiainen, J
    Marchais, S
    McCarron, J
    Halldin, C
    Sovago, J
    Gulyas, B
    Truong, P
    Wikström, H
    Farde, L
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 359P - 360P
  • [3] Brain serotonin 5-HT1A receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635
    Tauscher, J
    Kapur, S
    Verhoeff, NPLG
    Hussey, DF
    Daskalakis, ZJ
    Tauscher-Wisniewski, S
    Wilson, AA
    Houle, S
    Kasper, S
    Zipursky, RB
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2002, 59 (06) : 514 - 520
  • [4] Imaging the 5-HT1A receptor in patients with schizophrenia and healthy controls using [11C]WAY-100635
    Lombardo, I
    Slifstein, M
    Fullerton, C
    Gil, R
    Hwang, DR
    Martin, J
    Frankle, W
    Fairbank, C
    Van Heertum, R
    Gorman, J
    Laruelle, M
    Abi-Dargham, A
    [J]. NEUROIMAGE, 2002, 16 (03) : S107 - S107
  • [6] FIRST DELINEATION OF 5-HT1A RECEPTOR IN HUMAN BRAIN WITH PET AND [C-11]WAY-100635
    PIKE, VW
    MCCARRON, JA
    LAMMERSTMA, AA
    HUME, SP
    POOLE, K
    GRASBY, PM
    MALIZIA, A
    CLIFFE, IA
    FLETCHER, A
    BENCH, C
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 283 (1-3) : R1 - R3
  • [7] [C-11] WAY-100635 - A RADIOLIGAND FOR IMAGING 5-HT1A RECEPTORS WITH POSITRON EMISSION TOMOGRAPHY
    MATHIS, CA
    SIMPSON, NR
    MAHMOOD, K
    KINAHAN, PE
    MINTUN, MA
    [J]. LIFE SCIENCES, 1994, 55 (20) : PL403 - PL407
  • [8] Two new C-methyl analogues of WAY-100635-preparation, labeling with carbon-11 and evaluation as PET radioligands for brain 5-HT1A receptors in monkey
    Pike, VW
    Tarkiainen, J
    Marchais, S
    McCarron, JA
    Halldin, C
    Sovago, J
    Gulyas, B
    Truong, P
    Wikstrom, HV
    Farde, L
    [J]. NEUROIMAGE, 2002, 16 (03) : S19 - S19
  • [9] Serotonin 5-HT1A Receptor Binding Potential Declines with Age as Measured by [11C]WAY-100635 and PET
    Johannes Tauscher
    N Paul LG Verhoeff
    Bruce K Christensen
    Doug Hussey
    Jeffrey H Meyer
    Alex Kecojevic
    Mahan Javanmard
    Siegfried Kasper
    Shitij Kapur
    [J]. Neuropsychopharmacology, 2001, 24 : 522 - 530
  • [10] Serotonin 5-HT1A receptor binding potential declines with age as measured by [11C]WAY-100635 and PET
    Tauscher, J
    Verhoeff, NPLG
    Christensen, BK
    Hussey, D
    Meyer, JH
    Kecojevic, A
    Javanmard, M
    Kasper, S
    Kapur, S
    [J]. NEUROPSYCHOPHARMACOLOGY, 2001, 24 (05) : 522 - 530